A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study - Banerjee, A; Jakacki, RI; Onar-Thomas, A (Neuro Oncol, 2017)
et al.